Atlanta, GA – Scibility Media – 10/10/2014
This article discusses three pharmaceutical stocks: Ironwood Pharmaceuticals, Inc.(NASDAQ:IRWD), Catalyst Pharmaceutical Partners, Inc.(NASDAQ:CPRX), and Avanir Pharmaceuticals Inc(NASDAQ:AVNR)
Ironwood Pharmaceuticals, Inc.(NASDAQ:IRWD) will be presenting linaclotide-related data at the American College of Gastroenterology 2014 Annual Scientific Meeting, which will be held from Oct. 17th to Oct. 22nd in Philadelphia. This presentation, which will address its efficacy on dyspepsia symptoms, will offer the company the chance to present its findings to a large audience that may be interested in supporting the work. Linaclotide, which is the company’s lead product candidate, would be used in the treatment of irritable bowl syndrome with constipations and chronic idiopathic constipation disorders.
Catalyst Pharmaceutical Partners, Inc.(NASDAQ:CPRX) will be presenting its top-line safety and efficacy results for the phase III trial of Firdapse at the 139th Annual Meeting of the American Neurological Association at The Baltimore Waterfront Marriott on Oct. 12th, 2014. According to the press release, the presentation will cover the drug’s effectiveness in the treatment of Lamber-Eaton Myasthenic Syndrome. The drug is the first of its kind to be approved in Europe.
Avanir Pharmaceuticals Inc(NASDAQ:AVNR) announced on Oct. 8th that it will be hosting an Investor Relations Briefing in New York City on Oct. 15th. Members of the company’s senior management team will offer information regarding the safety and efficacy of AVP-923 in Alzheimer’s patients. The company also plans to present information on the phase II trial of the drug, as well as a phase IV study of NUEDEXTA, at the American Neurological Association’s Annual Meeting in Baltimore.
EquiPress.com is a non-advertisement based network (currently in limited release) designed for investors to discover and communicate with publicly traded companies in real-time.
Sign-up for free now to experience the full benefits of EquiPress pre-launch.
Discover and communicate with companies you would otherwise never have seen based on your interests, company news, personalized news feeds, and one-on-one communications with no middle-men nor advertisements. Read our no advertisements pledge.
Can’t find your company on EquiPress? Send us an email to email@example.com and we will contact them for you.
Interested in a one month free trial? Get access to our private investor network, real-time news distribution, automatic disclaimers, corporate analytics, verified public profile, and industry-wide marketing of your corporate news.
Disclosure: EquiPress is not a registered investment adviser and nothing contained in any materials should be construed as a recommendation to buy or sell securities. EquiPress does not hold any equity or financial interest in any publicly traded company. If a company mentioned in this article is a client of EquiPress, we will explicitly state the relationship. EquiPress provides a uniform subscription based service to all publicly traded companies on a monthly basis at a rate of $495 to provide investor awareness. EquiPress receives only cash compensation from clients. Despite the relationship, EquiPress maintains a neutral stance (nonbiased) on any investment related opinions and exists solely for the purpose of allowing investors to communicate with the publicly traded companies in an effort to establish for themselves investment considerations. Investors should always conduct their own due diligence with any potential investment. Always seek help from a professional financial advisor. Please visit www.equipress.com for complete risks and disclosures.